Historical Valuation
Atara Biotherapeutics Inc (ATRA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.62 is considered Undervalued compared with the five-year average of 0.11. The fair price of Atara Biotherapeutics Inc (ATRA) is between 362.30 to 379.63 according to relative valuation methord. Compared to the current price of 17.44 USD , Atara Biotherapeutics Inc is Undervalued By 95.19%.
Relative Value
Fair Zone
362.30-379.63
Current Price：17.44
95.19%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Atara Biotherapeutics Inc (ATRA) has a current Price-to-Book (P/B) ratio of -3.50. Compared to its 3-year average P/B ratio of 1.68 , the current P/B ratio is approximately -308.56% higher. Relative to its 5-year average P/B ratio of 2.28, the current P/B ratio is about -253.59% higher. Atara Biotherapeutics Inc (ATRA) has a Forward Free Cash Flow (FCF) yield of approximately -54.48%. Compared to its 3-year average FCF yield of -180.10%, the current FCF yield is approximately -69.75% lower. Relative to its 5-year average FCF yield of -120.35% , the current FCF yield is about -54.73% lower.
P/B
Median3y
1.68
Median5y
2.28
FCF Yield
Median3y
-180.10
Median5y
-120.35
Competitors Valuation Multiple
AI Analysis for ATRA
The average P/S ratio for ATRA competitors is 236.55, providing a benchmark for relative valuation. Atara Biotherapeutics Inc Corp (ATRA.O) exhibits a P/S ratio of 2.62, which is -98.89% above the industry average. Given its robust revenue growth of -91.41%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ATRA
1Y
3Y
5Y
Market capitalization of ATRA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ATRA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ATRA currently overvalued or undervalued?
Atara Biotherapeutics Inc (ATRA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.62 is considered Undervalued compared with the five-year average of 0.11. The fair price of Atara Biotherapeutics Inc (ATRA) is between 362.30 to 379.63 according to relative valuation methord. Compared to the current price of 17.44 USD , Atara Biotherapeutics Inc is Undervalued By 95.19% .
What is Atara Biotherapeutics Inc (ATRA) fair value?
ATRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Atara Biotherapeutics Inc (ATRA) is between 362.30 to 379.63 according to relative valuation methord.
How does ATRA's valuation metrics compare to the industry average?
The average P/S ratio for ATRA's competitors is 236.55, providing a benchmark for relative valuation. Atara Biotherapeutics Inc Corp (ATRA) exhibits a P/S ratio of 2.62, which is -98.89% above the industry average. Given its robust revenue growth of -91.41%, this premium appears unsustainable.
What is the current P/B ratio for Atara Biotherapeutics Inc (ATRA) as of Jan 10 2026?
As of Jan 10 2026, Atara Biotherapeutics Inc (ATRA) has a P/B ratio of -3.50. This indicates that the market values ATRA at -3.50 times its book value.
What is the current FCF Yield for Atara Biotherapeutics Inc (ATRA) as of Jan 10 2026?
As of Jan 10 2026, Atara Biotherapeutics Inc (ATRA) has a FCF Yield of -54.48%. This means that for every dollar of Atara Biotherapeutics Inc’s market capitalization, the company generates -54.48 cents in free cash flow.
What is the current Forward P/E ratio for Atara Biotherapeutics Inc (ATRA) as of Jan 10 2026?
As of Jan 10 2026, Atara Biotherapeutics Inc (ATRA) has a Forward P/E ratio of 19.53. This means the market is willing to pay $19.53 for every dollar of Atara Biotherapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Atara Biotherapeutics Inc (ATRA) as of Jan 10 2026?
As of Jan 10 2026, Atara Biotherapeutics Inc (ATRA) has a Forward P/S ratio of 2.62. This means the market is valuing ATRA at $2.62 for every dollar of expected revenue over the next 12 months.